Nothing Special   »   [go: up one dir, main page]

ES2171158T3 - Derivados de oxatiolano cristalizados. - Google Patents

Derivados de oxatiolano cristalizados.

Info

Publication number
ES2171158T3
ES2171158T3 ES92109221T ES92109221T ES2171158T3 ES 2171158 T3 ES2171158 T3 ES 2171158T3 ES 92109221 T ES92109221 T ES 92109221T ES 92109221 T ES92109221 T ES 92109221T ES 2171158 T3 ES2171158 T3 ES 2171158T3
Authority
ES
Spain
Prior art keywords
oxatiolan
crystallized
derivatives
crystal form
bipiramidilo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92109221T
Other languages
English (en)
Inventor
Tony Gordon Roberts
Paul Evans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10696001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2171158(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2171158T3 publication Critical patent/ES2171158T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Secondary Cells (AREA)
  • Medicinal Preparation (AREA)

Abstract

(-)CIS-4-AMINO-1-(2-HIDROXIMETIL-1,3-OXATIOLAN-5-IL-)-(1H)PIRIMIDIN-2-ONA CON FORMA CRISTALINA, EN PARTICULAR CON FORMA DE AGUJA O DE CRISTALES DE BIPIRAMIDILO, FORMULACIONES FARMACEUTICAS DE LA MISMA, METODOS PARA SU PREPARACION Y SU USO EN MEDICINA.
ES92109221T 1991-06-03 1992-06-02 Derivados de oxatiolano cristalizados. Expired - Lifetime ES2171158T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919111902A GB9111902D0 (en) 1991-06-03 1991-06-03 Chemical compounds

Publications (1)

Publication Number Publication Date
ES2171158T3 true ES2171158T3 (es) 2002-09-01

Family

ID=10696001

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92109221T Expired - Lifetime ES2171158T3 (es) 1991-06-03 1992-06-02 Derivados de oxatiolano cristalizados.

Country Status (30)

Country Link
US (1) US5905082A (es)
EP (2) EP1099700A1 (es)
JP (1) JP2851480B2 (es)
KR (1) KR100244008B1 (es)
AP (1) AP300A (es)
AT (1) ATE212630T1 (es)
AU (2) AU1881092A (es)
BG (1) BG60914B1 (es)
CA (2) CA2070230C (es)
CZ (1) CZ284513B6 (es)
DE (1) DE69232387T2 (es)
DK (1) DK0517145T3 (es)
ES (1) ES2171158T3 (es)
GB (1) GB9111902D0 (es)
GE (1) GEP19991834B (es)
IE (2) IE20020782A1 (es)
IL (1) IL102073A (es)
IS (2) IS1867B (es)
MX (1) MX9202619A (es)
NO (1) NO301713B1 (es)
NZ (1) NZ242981A (es)
OA (1) OA09913A (es)
PT (1) PT517145E (es)
RU (1) RU2102393C1 (es)
SG (1) SG52455A1 (es)
SK (1) SK281249B6 (es)
TW (1) TW254939B (es)
UA (1) UA41265C2 (es)
WO (1) WO1992021676A1 (es)
ZA (1) ZA924007B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4581979A (en) * 1983-07-01 1986-04-15 Automotive Products Plc Shipping and installation restraining clip for master cylinder input member
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6346627B1 (en) * 1990-02-01 2002-02-12 Emory University Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
EP1655033A1 (en) 1995-06-07 2006-05-10 Emory University Nucleosides with anti-hepatitis B virus activity
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
DE69727240T2 (de) 1996-06-25 2004-11-25 Glaxo Group Ltd., Greenford Kombinationen, enthaltend VX478, Zidovudin und 3TC zur Behandlung von HIV
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
EP1903041B1 (en) * 2001-03-01 2015-02-18 AbbVie Inc. Polymorphic and other crystalline forms of cis-FTC
US6600044B2 (en) 2001-06-18 2003-07-29 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers
WO2003027106A1 (en) * 2001-09-25 2003-04-03 Cadila Healthcar Limited Process for the preparation of crystalline polymorph ii of lamivudine
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
JP2006508134A (ja) * 2002-11-08 2006-03-09 グラクソ　グループ　リミテッド 医薬組成物
WO2004064846A1 (en) 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
BRPI0517697A (pt) * 2004-11-10 2008-10-14 Chiron Corp interferon-beta deamidado
US20060242012A1 (en) * 2005-04-22 2006-10-26 Sumit Agarwal Determining or scoring properties to solicit to join ad network using advertiser or aggregated advertiser interest
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
WO2007119248A1 (en) * 2006-04-18 2007-10-25 Lupin Limited A novel crystalline form of lamivudine
WO2009031026A2 (en) * 2007-09-06 2009-03-12 Combino Pharm, S.L. Novel pharmaceutical compositions
US20100190982A1 (en) * 2007-09-17 2010-07-29 Janardhana Rao Vascuri Process for the preparation of lamivudine form i
EP2227478A1 (en) * 2007-11-29 2010-09-15 Ranbaxy Laboratories Limited Process and intermediates for the preparation of substituted 1, 3-oxathiolanes, especially lamivudine
AU2008331166B2 (en) * 2007-11-29 2013-10-10 Ranbaxy Laboratories Limited Process for the preparation of substituted 1,3-oxathiolanes
US20100324290A1 (en) * 2007-11-29 2010-12-23 Ranbaxy Laboratories Limited Crystalline form i of lamivudine and its preparation
WO2009127996A1 (en) * 2008-04-17 2009-10-22 Ranbaxy Laboratories Limited Novel crystalline form of lamivudine
EP2318398A4 (en) * 2008-09-01 2011-12-07 Hetero Research Foundation PROCESS FOR PREPARING A POLYMORPHIC FORM OF LAMIVUDIN
US20110288298A1 (en) * 2008-11-12 2011-11-24 Lupin Limited novel polymorph of emtricitabine and a process for preparing of the same
CN101531656B (zh) * 2009-03-24 2010-12-08 福建广生堂药业有限公司 拉米夫定晶型及其制备方法
CN101993439B (zh) * 2009-03-24 2013-04-24 福建广生堂药业股份有限公司 拉米夫定晶型及其制备方法
EP2435052B1 (en) * 2009-05-27 2015-07-15 Hetero Research Foundation Solid oral dosage forms of lamivudine with isomalt
WO2011007367A1 (en) 2009-07-15 2011-01-20 Lupin Limited An improved process for preparation of efavirenz
DK2488516T3 (en) 2009-10-14 2015-05-26 Mylan Lab Ltd Method of producing lamivudine and novel salts in the preparation thereof
KR101830715B1 (ko) 2010-01-27 2018-04-04 비이브 헬쓰케어 컴퍼니 Hiv 감염을 치료하기 위한 약학적 조합물
WO2011095987A1 (en) * 2010-02-03 2011-08-11 Matrix Laboratories Ltd. Novel process for the preparation of cis-nucleoside derivative
AU2011215878A1 (en) 2010-02-12 2012-08-09 Merck Sharp & Dohme Corp. Preparation of lamivudine Form I
EP2579892A2 (en) 2010-06-09 2013-04-17 Vaccine Technologies, Incorporated Therapeutic immunization in hiv infected subjects receiving stable antiretroviral treatment
US20130296562A1 (en) 2011-08-05 2013-11-07 Lupin Limited Stereoselective process for preparation of 1,3-oxathiolane nucleosides
WO2013168066A1 (en) 2012-05-05 2013-11-14 Lupin Limited An improved process for the manufacture of lamivudine form i.
CN114099454B (zh) * 2020-08-31 2023-06-27 长春海悦药业股份有限公司 一种拉米夫定片及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
JPH04358486A (ja) * 1991-06-04 1992-12-11 Toshiba Corp 高能率符号化信号処理装置

Also Published As

Publication number Publication date
IE921780A1 (en) 1992-12-16
AU656379B2 (en) 1995-02-02
CA2311988A1 (en) 1992-12-04
US5905082A (en) 1999-05-18
IS1867B (is) 2003-05-02
SK125793A3 (en) 1994-11-09
RU2102393C1 (ru) 1998-01-20
CA2070230C (en) 2004-08-03
NO922182L (no) 1992-12-04
BG98254A (bg) 1994-07-29
EP0517145B1 (en) 2002-01-30
NO922182D0 (no) 1992-06-02
JP2851480B2 (ja) 1999-01-27
IE20020782A1 (en) 2003-04-02
NO301713B1 (no) 1997-12-01
IL102073A (en) 1996-05-14
PT517145E (pt) 2002-07-31
KR100244008B1 (ko) 2000-03-02
JPH06211848A (ja) 1994-08-02
WO1992021676A1 (en) 1992-12-10
AP9200395A0 (en) 1992-07-31
ATE212630T1 (de) 2002-02-15
CA2070230A1 (en) 1992-12-04
OA09913A (en) 1994-09-15
DE69232387T2 (de) 2002-09-26
IL102073A0 (en) 1993-01-14
AU1881092A (en) 1993-01-08
SK281249B6 (sk) 2001-01-18
ZA924007B (en) 1993-04-28
GEP19991834B (en) 1999-11-05
BG60914B1 (bg) 1996-06-28
EP1099700A1 (en) 2001-05-16
EP0517145A1 (en) 1992-12-09
HK1009599A1 (en) 1999-06-04
SG52455A1 (en) 1998-09-28
AP300A (en) 1994-01-20
IS3873A (is) 1992-12-04
DK0517145T3 (da) 2002-05-06
UA41265C2 (uk) 2001-09-17
CA2311988C (en) 2005-11-15
CZ261293A3 (en) 1994-04-13
IS4268A (is) 1995-02-27
DE69232387D1 (de) 2002-03-14
KR930000511A (ko) 1993-01-15
MX9202619A (es) 1992-12-01
AU1736192A (en) 1993-03-11
TW254939B (es) 1995-08-21
NZ242981A (en) 1994-04-27
GB9111902D0 (en) 1991-07-24
CZ284513B6 (cs) 1998-12-16

Similar Documents

Publication Publication Date Title
ES2171158T3 (es) Derivados de oxatiolano cristalizados.
IT8719064A0 (it) Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive.
IT8847556A0 (it) Derivati peptidici, loro preparazione e loro impiego come medicamenti
IT8423747A0 (it) Derivati 2,6-disostituiti di naftalene, procedimento per prepararli e loro uso nel campo farmaceutico e cosmetico.
NO924183D0 (no) Farmasoeytiske preparater med regulert frigjoering
MX17752A (es) Formulaciones farmaceuticas y procedimiento para prepararlas
MX9204301A (es) Acilmercaptoalcanoildipeptidos, metodos de preparacion y su uso terapeutico.
FI881061A7 (fi) Hitaasti vapauttavia valmisteita ruoansulatuskanavan ulkopuolisesti annettaviksi ja niiden käyttö.
ES2051678T1 (es) Derivados de 5-oxo-l-prolina y uso farmaceutico de los mismos.
IT8847871A0 (it) Ne e loro impiego come medicamenti derivati peptidici,loro preparazio-
FI922983A7 (fi) Pyrimidiini-4-karboksamidijohdannaisia, niiden valmistus ja terapeuttinen käyttö
FI914611A7 (fi) 2-aminopyrimidiini-4-karboksamidijohdannaiset, niiden valmistus ja terapeuttinen käyttö
TR24895A (tr) PIRIMIDIN TüREVLERI,BUNLARIN ISTIHSAL EDILMESI VE KULLANILMASI
AR011441A1 (es) DERIVADOS ÉSTERES Y AMIDAS DE FENIL XANTINA ,PROCESOS PARA SU PREPARACIoN , FORMULACIONES FARMACÉUTICAS Y SU USO EN MEDICINA
IT1143047B (it) Composti diazepinici per uso farmaceutico e loro procedimento di preparazione
IT1237474B (it) Composti tripeptidici e loro uso farmaceutico come immuno-modulatori
IT8722682A0 (it) Compressa per uso oftalmico e rilascio controllato della sostanza attiva.
FI903214A7 (fi) Naftyyliamino- ja naftyylioksi-pyrimidiinit ja niihin liittyvät yhdisteet, menetelmä niiden valmistamiseksi ja niiden käyttö dermatologisinalääkeaineina
ITMI911470A1 (it) N-(5-tioxo-l-prolil)-l-cisteina e suoi derivati, loro preparazione ed impiego terapeutico
DK635988A (da) 1,3-butandiolacetoacetat-derivater og anvendelse af 1,3-butandiolacetoacetat-forbindelser til fremstilling af farmaceutiske praeparater
FI885056A7 (fi) Uusia fluorimetoksifenyylidihydropyridiinejä, menetelmiä niiden valmistamiseksi ja niiden käyttö lääkkeissä
FI941958A7 (fi) 2-heterosyklinenetyyliamiinijohdannaiset ja niiden käyttö lääkkeinä
AR229875A1 (es) Procedimiento para la preparacion de derivados de 4-sulfanoil fenil-3-sustituido-2-fenilimino-4-tiazolina,intermediarios para su uso exclusivo en el procedimiento y procedimiento para obtener preparados farmaceuticos
DE3877365D1 (de) Arzneimittel mit methylcellulose.
BR9106372A (pt) Derivados 1,5-benzotiazepinona,suas preparacoes e uso farmaceutico

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 517145

Country of ref document: ES